All News
Rituximab Efficacy in MAINRITSAN Long-Term Studies
The original randomized controlled, prospective MAINRITSAN study of 115 patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis [AAV]) demonstrated superiority of rituximab (RTX) over azathioprine (AZA) for maintenance of remission at 22 months in ANCA-associated vasculitis patients after CYC remission induction.
Read Article
2023 Rheumatology Year in Review
Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.
2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.
Read Article
The answer to "always" is "always" no, correct? PEXIVAS low dose is a great baseline plan, but always adjust in light of the individual patient both upfront and especially if things aren't working out @anisha_dua @RheumNow #RNL2024 https://t.co/RPnpAdB1eG
Richard Conway RichardPAConway ( View Tweet)
Rapid GC taper in ANCA vasculitis
#RNL2024 @RheumNow
@anisha_dua
PEXIVAS - reduced GC is safe, decreased ifns
Retrospective real world - 234 pts. Reduced dose GC+RTX increased death/ESKD HR 2.42. No difference in infections https://t.co/SWIUSyVbWb
Eric Dein ericdeinmd ( View Tweet)
Great talk @anisha_dua re:AAV, solid updates on mgmt decisions
Looking forward to debating this study with @lastwalsh w/@MatsJunek moderating... @TerrierBen any updates on when your RWD study will be published?
@RheumNow https://t.co/ywVaOIp2WJ
Mike Putman EBRheum ( View Tweet)
Contrasing ACR/VF and EULAR GPA guidelines from @anisha_dua @RheumNow #RNL2024 https://t.co/RLJx9fJHGk
Richard Conway RichardPAConway ( View Tweet)
"Real world studies: When people stop being polite and start getting real." Dr @anisha_dua #RNL2024
Comparing Walsh to Nagle in terms of primary outcomes, regimens, pt populations, and plasma exchange.
@RheumNow https://t.co/io8OGnWxdS
Dr. Rachel Tate uptoTate ( View Tweet)
Is there data for PLEX in GPA?
@anisha_dua #RNL2024 @RheumNow
PEXIVAS negative study
But subgroups show decreased dialysis...
But, no improvement in mortality and increased infection risk https://t.co/K9VbcNNsge
Eric Dein ericdeinmd ( View Tweet)
#RNL2024 @RheumNow
@anisha_dua
Throwing the kitchen sink in severe GPA
CYC + RTX combo - sick population (median GFR 9, 47% on HD, 52% DAH, all received PLEX too)
- 85% survival, 69% not ESKD, low rates of relapse (13% at 36 mos)
But, prolonged B cell depletion, aggressive Rx https://t.co/9AZFMQ3o9P
Eric Dein ericdeinmd ( View Tweet)
@anisha_dua reviews differences between EULAR vs ACR Vasculitis guidelines #RNL2024 @RheumNow https://t.co/1aIbnX5KBI
TheDaoIndex KDAO2011 ( View Tweet)
@anisha_dua reviews GPA management in 2024. Here are your ACR/VF 2021 and EULAR 2022 guideline updates. Review these regimen options for your patients. #RNL2024 @RheumNow https://t.co/SvQoe0YKKV
Dr. Rachel Tate uptoTate ( View Tweet)
Clinical Pearl!
@DrCassySims currently treats with ASA 81mg po daily during vasculitis pregnancies at 12 weeks for preeclampsia ppx.
She notes there is some data/use of 162mg po daily in Europe which may change the way we practice in the future.
#RNL2024 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Pregnancy in vasculitis checklist:
- goals and timeline
- disease activity in 12 mos
- is there end organ damage?
- Review Rx
- h/o clots/miscarriages, APLS?
- Check Ro/La
- Role for ASA?
- Refer to MFM
Catherine Sims #RNL2024 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
How do vasculitis pts do during pregnancy?
Variable due to different diagnoses of flares
Gatto 2012: TA 3% flare, GPA 45% flare
Fredi 2015: 35% flare
Nguyen 2021: LVV 25% flare, 36% SVV
-Catherine Sims
#RNL2024 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
You can still attend RheumNow Live!
Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis.
https://t.co/LzcVytLDij
Register: https://t.co/NWXKNhQzc5 https://t.co/ogAfTtH5Nk
Dr. John Cush RheumNow ( View Tweet)
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/MThzw2joGO https://t.co/PmrJjf9C3a
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - GCA & Steroid Weaning
Weaning steroids in chronic GCA patient
https://t.co/HtrzP43Ivr https://t.co/xZZlNmeqP1
Dr. John Cush RheumNow ( View Tweet)
Excited to be talking at https://t.co/hposbnLVdD!!
As usual, @RheumNow screen-grabbed me at an opportune moment 🤣😆
Highly recommend the conference; register live/online at the link above! https://t.co/XewJXRASi8
Mike Putman EBRheum ( View Tweet)
Experience the Future of Rheumatology at RheumNow Live 2024, just two weeks away!
Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights.
https://t.co/ny6R6QBq0j https://t.co/slHPPOQIDi
Links:
Dr. John Cush RheumNow ( View Tweet)
Experience the Future of Rheumatology at RheumNow Live 2024, just two weeks away!
Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights.
https://t.co/bbnb97MOHO https://t.co/QXO34ZmP2i
Links:
Dr. John Cush RheumNow ( View Tweet)
